Trials / Completed
CompletedNCT00100659
PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NIH
- Sex
- All
- Age
- 5 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children. The purpose of this study is also to determine whether PEG-2a in combination with RV or PEG-2a alone will result in a longer response rate in children with CHC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Interferon/ribavirin |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2008-08-01
- Completion
- 2010-02-01
- First posted
- 2005-01-05
- Last updated
- 2018-10-24
- Results posted
- 2013-07-01
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00100659. Inclusion in this directory is not an endorsement.